ScreenerHero

MBRX Moleculin Biotech, Inc.

NAS · US · Healthcare · Biotechnology · moleculin.com
0.4389USD-1.48%Mkt Cap: 8.95M $P/E: 0.05

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycli…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap8.95M USD
Enterprise Value1.71M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-33.56M USD
Revenue/Share—
Last Price0.4389 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees17
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)0.05
P/E (Forward)-0.00
PEG—
EV/EBITDA-0.06
EV/Revenue—
P/S—
P/B0.27
EPS (TTM)8.51
EPS (Forward)-110.50
52W Range
0.16142% of range15.75
52W High15.75 USD
52W Low0.1614 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-223.64%
ROA-151.68%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-22.73M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-166.75%
Net Debt-6.97M USD
Net Debt/EBITDA0.24
Balance Sheet
Debt/Equity0.02
Current Ratio0.94
Quick Ratio0.78
Book Value/Sh1.63 USD
Cash/Share0.37 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateFeb 1, 2021
Splits
Last Split1:25
Split DateDec 1, 2025
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)12.00 USD
Upside (mean)+2634.1%
Target Range2.000 USD – 31.00 USD
2.000+2634.1% to mean31.00
# Analysts3
Ownership
Shares Out.20.39M
Float17.03M
Insiders6.13%
Institutions8.19%
Short Interest
Short Ratio0.4d
Short % Float1.48%
Short % Out.1.48%
Shares Short287.61K
Short (prev mo.)316.39K
Technical
SMA 500.6798 (-35.4%)
SMA 2002.354 (-81.4%)
Beta2.00
S&P 52W Chg16.45%
Avg Vol (30d)1.00M
Avg Vol (10d)1.51M
Technical Indicators
RSI (14)32.2
MACD-0.1110
MACD Signal-0.1173
MACD Hist.+0.0063
BB Upper0.8626 USD
BB Middle0.6045 USD
BB Lower0.3463 USD
BB Width85.41%
ATR (14)0.0840 USD
Vol Ratio (20d)0.33x